Physiological levels of ATP negatively regulate proteasome function.
about
Mitochondrial and Ubiquitin Proteasome System Dysfunction in Ageing and Disease: Two Sides of the Same Coin?Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservationThe ubiquitin-proteasome system and cardiovascular diseaseTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesThe ubiquitin proteasome system and myocardial ischemiaReversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathwaysControl of mitochondrial biogenesis and function by the ubiquitin-proteasome systemA quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacyA novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growthProteasome inhibition prolongs survival during lethal hemorrhagic shock in ratsL-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivoEnhancement of proteasome function by PA28α overexpression protects against oxidative stress.Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanismsIntracellular ATP concentration contributes to the cytotoxic and cytoprotective effects of adenosineProteasome functional insufficiency in cardiac pathogenesis.Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibitionMicroRNA-mRNA regulatory networking fine-tunes the porcine muscle fiber type, muscular mitochondrial respiratory and metabolic enzyme activities.A microRNA-mediated decrease in eukaryotic initiation factor 2α promotes cell survival during PS-341 treatment.Age influences inflammatory responses, hemodynamics, and cardiac proteasome activation during acute lung injury.Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.Gambogic acid enhances proteasome inhibitor-induced anticancer activity.Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibitionGambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway.Gambogic acid suppresses pressure overload cardiac hypertrophy in rats.The Danger Signal Extracellular ATP Is an Inducer of Fusobacterium nucleatum Biofilm Dispersal.Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.The role of the proteasome in heart diseaseResveratrol Specifically Kills Cancer Cells by a Devastating Increase in the Ca2+ Coupling Between the Greatly Tethered Endoplasmic Reticulum and Mitochondria.Activation of lysosomal P2X4 by ATP transported into lysosomes via VNUT/SLC17A9 using V-ATPase generated voltage gradient as the driving force.The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention.The anticancer effect of cytotoxin 1 from Naja atra Cantor venom is mediated by a lysosomal cell death pathway involving lysosomal membrane permeabilization and cathepsin B release.Controlling amphiphilic copolymer self-assembly morphologies based on macrocycle/anion recognition and nucleotide-induced payload release.Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation.Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.Cooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein.
P2860
Q26796638-CCCE7838-D018-4FB4-92D6-90C79028D2D1Q27000202-F536A306-E149-4D72-A91E-18F11AC2B7EFQ27021582-616B3335-FE12-4876-A3AD-2E4DF57D032BQ27026951-9D1624C0-FDBB-4605-A0C7-58B201F7B650Q28280898-CA6B1A91-4544-49F8-AB0E-A8359C1779DCQ28306744-7FC1891A-4D84-4204-B5B1-20792BA33D4EQ33628850-28D497B8-D3D1-49BB-9E82-7B1F342928CAQ33636442-ED59DF59-07B1-44AF-B046-D93F0F10B5F9Q33729793-317728C4-830B-4242-89F9-D2878C559607Q34221890-595230A0-6088-4A96-9D6E-BC920B9AFF11Q34279164-19DD0945-E21E-4485-8835-DEC7FDBD5967Q34472177-2A003C4C-EFE5-4138-82AB-755514FD9B9EQ34534191-8EC7AF36-5D9E-41A5-A381-719FB2BD97A5Q34592321-EE3D861C-AE47-48DD-8C9E-E4AB92BE6CD5Q34619261-C2456939-0EAB-4B80-97C1-7FE2BEE0F034Q35009649-47AF86C2-E0B9-43EA-BA7A-87F3E82065CCQ35601400-A92B8C98-5E9E-4DF5-BB7F-9F01D32CFAEEQ35820457-67796205-16CF-48BE-B8DB-18C557183941Q36093412-E1191BB3-5828-47CA-962E-B0DF036BDC27Q36602355-31A90FE7-B5CA-49B1-A683-0D0145C971C5Q36726221-A9DB620D-3F8E-4BD0-B4F2-0188974E9F20Q36771950-5ABC9D9D-EC21-489F-A1C2-40B776CA4C96Q36869779-8A0D9E58-F0CB-4812-B8A2-C19969E91A31Q36972631-19695642-A6D9-4BF7-8DEC-AA4AB21B594DQ37116324-4E6B0F55-B205-48C9-94F2-72BAD0EDB560Q37285392-99E7D6A1-5B10-4998-9521-94B0A4555546Q37419095-E73C7496-B319-4644-8CB5-6866E0E62AD5Q37610733-DA75A758-64F0-43C7-A92C-34105F491F3BQ37619364-8987B5B9-D43D-46DE-A818-E416955B7DDEQ37706728-67053FD7-8A4B-4F2E-AA73-E54B7DABA1D9Q37745139-CA994FE8-E2F6-4F03-9093-083936809F01Q37788836-CF58834D-5317-4F93-A4BE-F0CBA0667075Q38747609-8FCC5766-92D5-40EB-8372-89BD5DDB567BQ38754504-A8C65D92-5161-4F24-BAB5-8D25233BB433Q39079514-00192D48-5837-41F4-80C7-92771AB6BD2EQ39147019-576989AF-ECF3-480D-8EED-FD41ACB9EBDFQ41042676-95F867D9-3E1A-432F-9A86-C4CB4DF6F1EDQ41806996-BE2EC85B-F4F9-4332-98EE-A7DF9B251C88Q42023703-F81DC34F-E2D0-49D6-BC20-CCA3C2650BAEQ42284764-E2004285-899B-405A-A7E3-B9FC470053E2
P2860
Physiological levels of ATP negatively regulate proteasome function.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Physiological levels of ATP negatively regulate proteasome function.
@ast
Physiological levels of ATP negatively regulate proteasome function.
@en
Physiological levels of ATP negatively regulate proteasome function.
@nl
type
label
Physiological levels of ATP negatively regulate proteasome function.
@ast
Physiological levels of ATP negatively regulate proteasome function.
@en
Physiological levels of ATP negatively regulate proteasome function.
@nl
prefLabel
Physiological levels of ATP negatively regulate proteasome function.
@ast
Physiological levels of ATP negatively regulate proteasome function.
@en
Physiological levels of ATP negatively regulate proteasome function.
@nl
P2093
P2860
P356
P1433
P1476
Physiological levels of ATP negatively regulate proteasome function
@en
P2093
Canguo Zhao
Change Zhang
Changshan Yang
Emily McDowell
Guangmei Wen
Haiping Guo
Hongbiao Huang
Jinbao Liu
Ningfang Ma
P2860
P2888
P304
P356
10.1038/CR.2010.123
P50
P577
2010-08-31T00:00:00Z